CareLit · DOI-Nachweis · Pneumologie
Can health-economic modeling be adjusted to assess the cost-effectiveness of prognostic testing in COPD management?
DOI 10.1055/s-0034-1376778
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Wacker, R Holle, R Leidl
ZeitschriftPneumologie
Ausgabe06/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Genetic mutations like ADRB2 polymorphisms are suspected to influence treatment outcomes in COPD [1]. Clinical application of pharmacogenetic testing may improve treatment and cost outcomes in COPD. This paper analyzes whether effectiveness and cost-effectiveness of genetic testing for mutations and stratified treatment can be assessed by testing and adapting an existing COPD Markov model. Methods: The G…
Zitieren
Zitierempfehlung
M Wacker, R Holle, R Leidl (2014) Can health-economic modeling be adjusted to assess the cost-effectiveness of prognostic testing in COPD management?. Pneumologie (06). https://doi.org/10.1055/s-0034-1376778
Mit CareLit weiterarbeiten